Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Cancer Immunol Res. 2020 Mar 25;8(6):794–805. doi: 10.1158/2326-6066.CIR-19-0619

Fig. 5. IL21 and Panobinostat (Pano) cooperated to induce CD28+CD62L+ cells.

Fig. 5.

(A) Representative plots of CD28 and CD62L expression on CTLs expanded with the indicated conditions for 2 weeks. The numbers within the plots annotate the percentage of cells in each quadrant. (B) Percentage of CD28+CD62L+ cells in CTLs expanded with the indicated conditions from independent experiments (n=5; ** p<0.01; one-way ANOVA, as compared to CTLs expanded with the regular protocol). (C) Percentage of target tumor cell killing by CTLs expanded with the indicated condition from independent experiments (n=5; ** p<0.01; one-way ANOVA). (D) Percentage of IFN-γ+ or TNF-α+ cells and GZMb MFI of CTLs expanded with the indicated condition from independent experiments GZMb: granzyme B. (n=5, * p<0.05, ** p<0.01; ns: not significant, one-way ANOVA). The representative results out of five (A) independent experiments are shown.